Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr20.60 SEK
Change Today -0.10 / -0.48%
Volume 107.0K
OASM On Other Exchanges
Symbol
Exchange
Stockholm
As of 11:30 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

oasmia pharmaceutical ab (OASM) Snapshot

Open
kr20.70
Previous Close
kr20.70
Day High
kr20.80
Day Low
kr20.40
52 Week High
06/16/14 - kr24.17
52 Week Low
10/13/14 - kr16.34
Market Cap
2.0B
Average Volume 10 Days
381.6K
EPS TTM
kr-1.27
Shares Outstanding
97.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OASMIA PHARMACEUTICAL AB (OASM)

Related News

No related news articles were found.

oasmia pharmaceutical ab (OASM) Related Businessweek News

No Related Businessweek News Found

oasmia pharmaceutical ab (OASM) Details

Oasmia Pharmaceutical AB (publ) researches, develops, and manufactures drugs for human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company’s drug candidates for human health include Paclical that has completed Phase III clinical trial for the treatment of ovarian cancer, as well as is in Phase I clinical trial for treating metastatic breast cancer; Doxophos, a formulation of the cytostatic doxorubicin in Phase I clinical trial for the treatment of cancer; Docecal, a patented formulation of cytostatic docetaxel, which is in pre-clinical stage for the treatment of breast cancer; and OAS-19 that is in pre-clinical stage to treat various cancers. Its product candidates for animal health comprise Paccal Vet-CA1, a formulation of paclitaxel for the treatment of mastocytoma, mammary carcinoma, and squamous cell carcinoma in dogs; and Doxophos Vet, a Phase I clinical trial product for the treatment of lymphoma in dogs. Oasmia Pharmaceutical AB was founded in 1990 and is based in Uppsala, Sweden.

79 Employees
Last Reported Date: 03/5/15
Founded in 1990

oasmia pharmaceutical ab (OASM) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: kr1.3M
Compensation as of Fiscal Year 2014.

oasmia pharmaceutical ab (OASM) Key Developments

Oasmia Pharmaceutical AB (publ) Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended January 31, 2015

Oasmia Pharmaceutical AB (publ) reported unaudited consolidated earnings results for the third quarter and nine months ended January 31, 2015. For the quarter, the company reported net sales of SEK 482,000 against SEK 16,000 a year ago. Operating loss was SEK 25,479,000 against SEK 28,492,000 a year ago. Loss before taxes was SEK 27,713,000 against SEK 30,436,000 a year ago. Loss attributable to shareholders of the parent company was SEK 27,713,000 or SEK 0.30 per before and after dilution share against SEK 30,436,000 or SEK 0.37 per before and after dilution share a year ago. Cash outflow from operating activities was SEK 27,194,000 against SEK 26,261,000 a year ago. Investments in intangible assets were SEK 2,903,000 against SEK 6,025,000 a year ago. Investments in property, plant and equipment were SEK 758,000 against SEK 197,000 a year ago. For the nine months, the company reported net sales of SEK 2,034,000 against SEK 40,000 a year ago. Operating loss was SEK 79,975,000 against SEK 62,851,000 a year ago. Loss before taxes was SEK 87,416,000 against SEK 67,321,000 a year ago. Loss attributable to shareholders of the parent company was SEK 87,416,000 or SEK 0.98 per before and after dilution share against SEK 67,321,000 or SEK 0.82 per before and after dilution share a year ago. Cash outflow from operating activities was SEK 82,888,000 against SEK 60,418,000 a year ago. Investments in intangible assets were SEK 13,133,000 against SEK 23,912,000 a year ago. Investments in property, plant and equipment were SEK 2,771,000 against SEK 259,000 a year ago. Net debt at January 31, 2015 was SEK 1,439,000 against at January 31, 2014 SEK 126,632,000. Net sales were primarily of Paccal Vet-CA1 sales revenue. The decrease in net income compared to the corresponding period in the previous year was attributable to increased costs for method development costs in production at Oasmia and its contract manufacturers, increased purchases of raw materials and supplies for production as well as increased personnel expenses, decreased operating income and increased interest expenses for loans. The increase in cash outflow from operating activities compared to the corresponding period in the previous year is attributable to a significant decrease in operating income.

Oasmia Pharmaceutical AB Initiates Clinical Phase II Study with Doxophos Vet for the Treatment of Canine Lymphoma

Oasmia Pharmaceutical AB announced that the company has initiated a clinical Phase II study of Doxophos Vet for the treatment of canine lymphoma. The study, which will be conducted at two clinics in the USA and one clinic in Sweden, includes five dose cycles in total, and approximately 17 dogs receive doses of 35 mg/m2. Dogs weighing less than 10 kg receive 1,2 mg/m 2. The treatment is performed in three week intervals. The primary parameter of study in the clinical Phase II study is the response rate in the treated dogs after five cycles. The study, including report and follow-up, is estimated to be on-going during 2016. In a separate follow-up study, time to progression will be monitored.

Oasmia Pharmaceutical AB (publ)(OM:OASM) dropped from OMX Nordic Small Cap Index

Oasmia Pharmaceutical AB (publ) will be removed from OMX Nordic Small Cap Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OASM:SS kr20.60 SEK -0.10

OASM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OASM.
View Industry Companies
 

Industry Analysis

OASM

Industry Average

Valuation OASM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 79.8x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 75.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OASMIA PHARMACEUTICAL AB, please visit www.oasmia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.